Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.50 USD
Change Today -0.01 / -0.13%
Volume 623.0K
CALA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
OTC US
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

calithera biosciences inc (CALA) Snapshot

Open
$7.45
Previous Close
$7.51
Day High
$7.51
Day Low
$7.11
52 Week High
12/15/14 - $33.48
52 Week Low
10/10/14 - $6.51
Market Cap
134.6M
Average Volume 10 Days
1.8M
EPS TTM
--
Shares Outstanding
17.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CALITHERA BIOSCIENCES INC (CALA)

Related News

No related news articles were found.

calithera biosciences inc (CALA) Related Businessweek News

No Related Businessweek News Found

calithera biosciences inc (CALA) Details

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience’s portfolio of arginase inhibitors for use in human healthcare. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

37 Employees
Last Reported Date: 03/27/15
Founded in 2010

calithera biosciences inc (CALA) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $560.0K
Senior Vice President of Drug Discovery
Total Annual Compensation: $405.0K
Senior Vice President of Development
Total Annual Compensation: $405.0K
Senior Vice President of Research
Total Annual Compensation: $364.1K
Compensation as of Fiscal Year 2014.

calithera biosciences inc (CALA) Key Developments

Calithera Biosciences Selects Immuno-Oncology Clinical Candidate CB-1158, Oral Arginase Inhibitor for Treatment of Cancer

Calithera Biosciences, Inc. announced at the JMP Securities Life Sciences Conference in New York City, the selection of CB-1158 as the clinical candidate for their immuno-oncology program targeting inhibition of arginase, a critical immunosuppressive enzyme secreted by myeloid-derived suppressor cells (MDSCs) in tumors. Calithera anticipates submitting an Investigational New Drug (IND) application to the FDA for its first in class oral arginase inhibitor for the treatment of cancer near the end of the first quarter of 2016. Arginase exerts its immunosuppressive effect by depleting the amino acid arginine in the tumor microenvironment and preventing the immune system's cytotoxic T-cells and natural killer (NK) cells from proliferating and killing the tumor. Inhibition of arginase activity reverses this immunosuppressive block and restores T-cell function. Calithera has discovered novel, orally active arginase inhibitors that have shown inhibition of tumor growth in immunocompetent syngeneic mice. This inhibition of tumor growth is accompanied by a rapid increase in the local concentration of arginine, resulting in a rise in the number of CD3+ T-cells within the tumor. This is similar to what happens when indoleamine 2,3-dioxygenase (IDO) inhibitors block the degradation of tryptophan by IDO, leading to restoration of tryptophan levels in the tumor and activation of tumor-associated T-cells. CB-1158 has the potential for anti-tumor activity in renal cell cancer, breast cancer, non-small cell lung cancer, acute myeloid leukemia, and other tumor types where arginase-secreting MDSCs are known to play an immunosuppressive role. CB-1158 may also have the ability to combine with other immuno-oncology therapies that target T-cell activation, such as CTLA-4 and PD-1 antibodies.

Calithera Biosciences, Inc. - Special Call

To review the clinical data presented at ASCO from the ongoing Phase I study of CB-839

Calithera Biosciences, Inc. Reports Initial Phase I Data for Cb-839 in Patients with Acute Leukemias

Calithera Biosciences, Inc. announced that data from it’s lead, first-in-class program CB-839 will be presented at the 20thCongress of the European Hematology Association (EHA) June 11, 2015 to June 20, 15, 2015, in Vienna, Austria. These preliminary data demonstrate the clinical activity, tolerability and unique mechanism of action of CB-839 in patients with acute leukemia. As of March 1, 2015, fifteen patients with acute myeloid leukemia (AML) had been treated in Calithera's Phase I clinical trial of CB-839 in patients with relapsed or refractory acute leukemias.  Oral CB-839 was administered continuously in 21-day treatment cycles from 100 mg to 1,000 mg three times daily. There were no dose limiting toxicities identified.  Treatment-related adverse events of any grade that occurred in >10% of patients were limited to increases in transaminases (4 patients) and bilirubin (2 patients).  There were no Grade =3 adverse events that were considered treatment-related in >10% of patients. Stable disease for 4-10 cycles was observed in 5 (33%) of 15 efficacy-evaluable AML patients across all dose levels, with patients remaining on study for an average of 134 days (>6 cycles). One of these patients achieved a complete response in the bone marrow with incomplete recovery of peripheral counts (CRi) after 6 cycles of dosing.  All of the patients with stable disease or better were over 65 years of age, and not eligible for high dose therapy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CALA:US $7.50 USD -0.01

CALA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CALA.
View Industry Companies
 

Industry Analysis

CALA

Industry Average

Valuation CALA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CALITHERA BIOSCIENCES INC, please visit www.calithera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.